Literature DB >> 16260112

Steroid hormone receptor expression in male breast cancer.

C E Murphy1, P J Carder, M R J Lansdown, V Speirs.   

Abstract

AIMS: To investigate expression of the steroid hormone receptors estrogen receptor (ER)-alpha and -beta, progesterone receptor (PR) and androgen receptor (AR) in male breast cancer.
METHODS: Specimens from 16 male breast cancers were immunostained for ERalpha, ERbeta, PR and AR.
FINDINGS: Eighty-seven percent of tumours expressed ERalpha, 93% PR, 87% ERbeta and 87% AR. Staining for ERalpha and PR was confined exclusively to the nuclei of epithelial cells with some heterogeneity. Nuclear immunoreactivity was also observed with AR. Again this was restricted to epithelial cells but tended to be more uniform. ERbeta was seen in the nuclei of epithelial cells and also in stromal fibroblasts and lymphocytes. Analysis of serial sections revealed a similar pattern of staining with ERbeta and AR in epithelial cells.
CONCLUSIONS: In addition to expression of the better known steroid receptors, ERalpha, PR and AR, we have demonstrated a high rate of expression of ERbeta in male breast cancer. This is in keeping with the generally high steroid receptor expression seen in males. However, the abundance of ERbeta expressed in this small series of male breast cancer is in contrast to female breast cancer where ERbeta expression is often reduced.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16260112     DOI: 10.1016/j.ejso.2005.09.013

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  12 in total

1.  Male breast carcinoma: a clinicopathological and immunohistochemical characterization study.

Authors:  Ruoji Zhou; Lin Yu; Shuling Zhou; Rui Bi; Ruohong Shui; Baohua Yu; Hongfen Lu; Xu Cai; Wentao Yang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 2.  Breast and prostate cancer: more similar than different.

Authors:  Gail P Risbridger; Ian D Davis; Stephen N Birrell; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

3.  Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series.

Authors:  Giovanna Masci; Michele Caruso; Francesco Caruso; Piermario Salvini; Carlo Carnaghi; Laura Giordano; Vittoria Miserocchi; Agnese Losurdo; Monica Zuradelli; Rosalba Torrisi; Luca Di Tommaso; Corrado Tinterri; Alberto Testori; Carlos A Garcia-Etienne; Wolfgang Gatzemeier; Armando Santoro
Journal:  Oncologist       Date:  2015-05-06

4.  Male occult triple-negative breast cancer.

Authors:  Basma Alsayed; Hussain Adnan Abdulla; Hadi Alaskar; Ali Dhaif
Journal:  BMJ Case Rep       Date:  2019-04-20

5.  Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma.

Authors:  Kiyoshi Takagi; Takuya Moriya; Masafumi Kurosumi; Kimako Oka; Yasuhiro Miki; Akiko Ebata; Takashi Toshima; Shoji Tsunekawa; Hiroyuki Takei; Hisashi Hirakawa; Takanori Ishida; Shin-Ichi Hayashi; Junichi Kurebayashi; Hironobu Sasano; Takashi Suzuki
Journal:  Horm Cancer       Date:  2012-10-18       Impact factor: 3.869

Review 6.  Minireview: nuclear receptors and breast cancer.

Authors:  Suzanne D Conzen
Journal:  Mol Endocrinol       Date:  2008-04-16

Review 7.  Papillary carcinoma of breast: Minireview.

Authors:  Sachin B Ingle; Hemant G Murdeshwar; Saleha Siddiqui
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

8.  Treatment outcomes for male breast cancer: a single-centre retrospective case-control study.

Authors:  M Rushton; A Kwong; H Visram; N Graham; W Petrcich; S Dent
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

Review 9.  Male breast carcinoma: increased awareness needed.

Authors:  Jonathan White; Olive Kearins; David Dodwell; Kieran Horgan; Andrew M Hanby; Valerie Speirs
Journal:  Breast Cancer Res       Date:  2011-09-29       Impact factor: 6.466

10.  A Prognostic Analysis of Male Breast Cancer (MBC) Compared with Post-Menopausal Female Breast Cancer (FBC).

Authors:  Xing-Fei Yu; Hong-Jian Yang; Yang Yu; De-Hong Zou; Lu-Lu Miao
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.